This clinical trial will determine whether focused ultrasound can safely and effectively treat metastatic brain tumors when ...

"GRIN Therapeutics begins Phase III trial of radiprodil for NDD" was originally created and published by Clinical Trials ...

Their shared dedication reflects a broader mission to bring meaningful change to women’s health, offering hope and tangible ...

With the right policy support, the sector can reach a size of USD 120-130 billion by 2030, and expand further to about USD ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

Endometriosis is a chronic, estrogen-dependent condition affecting an estimated 10% of women of reproductive age worldwide ...

Eikon Therapeutics is planning to become the second biotech to go public in 2026, in another sign that the public markets are ...

Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19 ...

Zymeworks (ZYME) posts strong Phase 3 Ziihera data in HER2+ GEA and eyes up to $440M in milestones plus royalties—read the ...

Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment ...

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said its experimental immune therapy nipocalimab cleared a major clinical ...

Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...